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Abstract
PTPN22 is a tyrosine phosphatase and functions as a damper of TCR signals. A C-to-T single nucleotide polymorphism (SNP)
located at position 1858 of human PTPN22 cDNA and converting an arginine (R620) to tryptophan (W620) confers the
highest risk of rheumatoid arthritis among non-HLA genetic variations that are known to be associated with this disease.
The effect of the R-to-W conversion on the phosphatase activity of PTPN22 protein and the impact of the minor T allele of
the C1858T SNP on the activation of T cells has remained controversial. In addition, how the overall activity of PTPN22 is
regulated and how the R-to-W conversion contributes to rheumatoid arthritis is still poorly understood. Here we report the
identification of an alternative splice form of human PTPN22, namely PTPN22.6. It lacks the nearly entire phosphatase
domain and can function as a dominant negative isoform of the full length PTPN22. Although conversion of R620 to W620
in the context of PTPN22.1 attenuated T cell activation, expression of the tryptophan variant of PTPN22.6 reciprocally led to
hyperactivation of human T cells. More importantly, the level of PTPN22.6 in peripheral blood correlates with disease activity
of rheumatoid arthritis. Our data depict a model that can reconcile the conflicting observations on the functional impact of
the C1858T SNP and also suggest that PTPN22.6 is a novel biomarker of rheumatoid arthritis.
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Introduction
Recent studies have identified more than 30 SNPs that are
associated with a higher risk of rheumatoid arthritis (RA). One of
the SNPs is located within PTPN22 [1]. This SNP (C1858T,
rs2476601) converts an arginine (R620) to a tryptophan (W620)
and confers the highest risk of RA among known non-HLA
genetic variations [1,2,3,4]. It is also associated with several other
autoimmune diseases, including lupus and autoimmune diabetes
[5,6]. PTPN22 is a non-receptor tyrosine phosphatase that is
expressed preferentially in hematopoietic cells [7,8]. It contains a
catalytic domain in its N-terminus, which is followed by an
inhibitory domain [9], and four proline rich domains in its C-
terminus. Its substrates include several cytoplasmic signaling
molecules, such as Lck, Zap70, Grb2, Csk, and Vav
[10,11,12,13]. Previous studies in human and mouse have
established that PTPN22 is a negative regulator of the TCR
signals in lymphocytes [1,2,14].
Several studies have indicated that the C1858T SNP creates a
biochemical gain-of-function variant [1,2,15]. W620PTPN22
attenuates TCR-induced NFAT activity more potently than
R620PTPN22 when expressed in Jurkat T cells [2]. One study
however demonstrates that co-expression of W620PTPN22 and
one of its substrates Csk unmasks the 1858T allele as a hypomorph
[16]. A recent study further suggests that the R-to-W conversion
strengthens the interaction between PTPN22 and calpain 1
protease and leads to enhanced degradation of PTPN22, thereby
creating a hypomorphic protein [17]. Human T cells obtained
from healthy individuals carrying the 1858T allele and expressing
W620PTPN22 have been shown to be hyper-responsive or hypo-
responsive to stimulation in different studies [17,18]. Thus, the
effect of the C1858T SNP on the activity of PTPN22 and on the
activation of lymphocytes has remained controversial. It is also
unclear how the 1858T allele increases the risk of RA.
Furthermore, how the overall activity of PTPN22 is regulated is
largely unknown.
Here we report the identification of a novel alternative splice
form of PTPN22, namely PTP22.6. We further characterize the
expression and function of PTPN22.6, and explore its clinical
applications in RA.
Methods
Preparation of human PBMC and Th cells
Peripheral blood mononuclear cells (PBMC) of normal blood
donors were isolated from buffy coats purchased from Research
Blood Components, LLC (Boston, MA) through an IRB (Partners
Human Research Committee)-approved protocol. Th cells were
enriched from PBMC with CD4 Microbeads (120-000-440,
Miltenyi Biotec, Auburn, CA).
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Human peripheral blood Th cells described in the previous
section and Jurkat cells (TIB-152
TM, ATCC) were cultivated in
RPMI-1640. In some experiments, Th cells and Jurkat cells were
stimulated with 2.5 mg/ml of plate bound anti-CD3 (Hit3a, Cat.
#300314, BioLegend, San Diego, CA) and 2 mg/ml of soluble
anti-CD28 (CD28.2, Cat. #302914, BioLegend) in the presence of
IL-2 (50 unit/ml) for indicated amount of time. Human colonic
adenocarcinoma cell line HT-29 cells (HTB38, ATCC) and
human embryonic kidney cells 293T (CRL-11268
TM, ATCC)
were cultivated in McCoy’s 5A medium (Gibco, Grand Island,
NY) and DMEM, respectively.
Plasmid, transfection and luciferase assay
cDNA encoding PTPN22.1 was amplified directly from Jurkat
cells with primers 59-CGGGATCCTTGCTCTGCAGCATG-
GACCAAAGA-39 and 59-GACGTCGACGCGTTTAAATAT-
TCCAAGTTGGTGGT-39. cDNA clone AK310570 (PTPN22.6)
was obtained from NITE Biological Resource Center (Chiba,
Japan). The 39 end of Lyp2 cDNA came from the 39 end of a
cDNA fragment amplified from Jurkat cells with primers 59-C-
GGGATCCTTGCTCTGCAGCATGGACCAAAGA-39 and 59-
GACGTCGACGCGTCTAAAGCCAAGAGAAATTTTTACC-
39, and pieced together with the 59 end of PTPN22.1 cDNA to
create the full-length Lyp2. All cDNA fragments were cloned into
an N-terminal FLAG-tag expression vector pCMV-Tag 2B
(Stratagene, La Jolla, CA). Transfection of 293T cells was
performed with Effectene Transfection Reagent (Cat. #301427,
Qiagen, Valencia, CA). Transfection of Jurkat cells was performed
with electroporation with Gene Pulser II (Bio-Rad, Hercules, CA)
set at 374 V/1050 mF. Luciferase activity was determined with
Dual-LuciferaseH Reporter Assay System (Promega, Madison,
WI). Firefly lucifease activity was then normalized against Renilla
luciferase activity. 3xNFAT-Luc and pTK-Renilla lucifease vector
were described previously [19]. Amaxa nucleofection (Amaxa
Biosystems, Gaithersburg, MD) was performed according to the
manufacturer’s instruction. Briefly, 5 millions human CD4+ T
cells were suspended in 100 ml of Human T cell Nucleofector
solution (VPA-1002) and transfected with 5 mg of plasmid DNA.
Antibodies, Western blotting, and immunoprecipitation
The following antibodies were used: human Lyp antibody
AF3428 (R&D Systems, Minneapolis, MN); Hsp90 a/b antibody
H-114 (sc-7947, Santa Cruz Biotechnology, Inc. Santa Cruz, CA);
FLAG antibody F3165 (Sigma-Aldrich, St. Louis, MO).
PTPN22.6 antibody was generated by immunizing rabbits with
a modified peptide (KC-IWEYSVLIIPENFS) corresponding to
the junctional sequence between exon 4 and 10. Immunoprecip-
itation of PTPN22.6 was performed by incubating 500 mgo f
whole Jurkat cell lysate with 2 mg of anti-Lyp and control goat IgG
(sc-2028, Santa Cruz Biotechnology).
Real-Time PCR
RNA isolation, reverse transcription, and real-time PCR were
performed as described [20]. The following primer pairs were
used: ‘‘total’’ 59-GCAGAAGTTCCTGGATGAG-39 and 59-TC-
AGCCACAGTTGTAGGATAG-39; PTPN22.1 59- TGCCCAC-
CAAACAAGCC-39 and 59-TGGTGGTGGATTCCTTGG-39;
PTPN22.6 59-TTTGCCCTATGATTATAGCCG-39 and 59-
GTTCTCAGGAATTATAAGGACACT-39; b-actin 59-GTGA-
CAGCAGTCGGTTGGAG-39 and 59-AGGACTGGGCCATT-
CTCCTT-39. The efficiency of the primers is 97.5% for ‘‘total’’,
100.3% for PTPN22.1, 104.1% for PTPN22.6, and 98.2% for b-
actin. The efficiency was calculated with MxPro
TM QPCR
software (Stratagene). The recommended efficiency is between
90% and 110%. All real-time PCR reactions were done in
duplicate using Brilliant II SYBR Green QPCR Master Mix (Cat.
#600828, Stratagene) on a Stratagene Mx3000P qPCR machine.
siRNA transfection
One million Jurkat cells were resuspended with 400 ml Opti-
mem I containing 400 pmole of siRNA and subjected to
electroporation with Gene Pulser II (Bio-Rad) set at 250 V/
400 mF. Human PTPN22 ON-TARGETplus SMARTpool
siRNA (L-008066-00-0005) and ON-TARGETplus Non-targeting
siRNA (D-001810-01-05) were purchased from Dharmacon/
Thermo Scientific (Lafayette, CO).
ELISA
IL-2 production was quantified by sandwich ELISA using anti-
human IL-2 (Cat. #555051) and biotinylated anti-human IL-2
(Cat. #555040) purchased from BD Pharmingen (San Diego, CA).
Rheumatoid arthritis samples and statistical analysis
The Brigham and Women’s Hospital Rheumatoid Arthritis
Sequential Study (BRASS) Registry has been described previously
[21]. All participants were recruited through an IRB (Partners
Human Research Committee)-approved written informed consent.
The diagnoses of RA were verified according to 1987 ACR criteria.
Whole peripheral blood was collected in PAXgene tubes (Qiagen).
Total RNAwas then prepared from the PAXgene tubes according to
the manufacturer’s instructions. Disease activity was determined with
DAS28-CRP3 (Disease Activity Score based on 28 joint counts with 3
variables including C-reactive protein) and was calculated based on
the equation DAS28-CRP3=[0.566!(tender joint count)+0.286!(s-
wollen joint count)+0.36 lognat(CRP+1)]61.10+1.15. Correlation
between the level of PTPN22 isoforms and DAS28-CRP3 was
determined with Linear Regression Models considering gender,
status of RF, and status of anti-CCP as variables.
Results
PTPN22.6 is a novel alternative splice form of PTPN22
A spliced variant of PTPN22, namely Lyp2, missing the C-
terminal three proline rich domains has been reported [8].
Intriguingly, we have also found in NCBI Gene database a cDNA
sequence (AK310570) corresponding to a novel spliced variant of
human PTPN22 (Figure 1A). AK310570 lacks exons 5–9, which
encode nearly the entire PTP domain. It also lacks exon 21 but
includes at its C-terminus 8 novel amino acid residues encoded by
the genomic sequence immediately following exon 20 (Figure S1).
We named the full-length version of PTPN22 and this novel
isoform PTPN22.1 and PTPN22.6, respectively. When expressed
in 293T cells, FLAG-fused PTPN22.1 and Lyp2 gave rise to
protein products of 92 kd and 79 kd, respectively (Figure 1B).
However, the actual molecular weight of FLAG-PTPN22.6 was
slightly bigger than the expected 76 kd. We were able to amplify
the full length PTPN22.1 and PTPN22.6 directly from human T
cells (data not shown), confirming the presence of PTPN22.6
transcript in T cells. However, we were unable to do so for full-
length Lyp2 despite several attempts with various primer pairs.
Thus, the existence of Lyp2 is still questionable and we decided
not to further investigate Lyp2.
Expression of PTPN22.6 in human T cells
To examine the expression kinetics of PTPN22.6 in human T
cells, we prepared cDNA from human primary CD4+ T cells that
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time. The cDNA was then subjected to real-time PCR with
primers specific to PTPN22.1 and PTPN22.6 (Figure 1A). We also
designed a pair of primer targeting the 59 region shared by both
PTPN22.1 and PTPN22.6 to quantify ‘‘total’’ PTPN22 expres-
sion. The results thus generated with the ‘‘total’’ and PTPN22.1
primers were very comparable, indicating that PTPN22.1 is the
dominant species of PTPN22 transcripts. We henceforth used
‘‘total’’ and PTP22.1 primers interchangeably. We measured the
level of PTPN22.1 and PTPN22.6 in T cells obtained from three
healthy donors. We found that the level of PTPN22.1 transcript
gradually increased and eventually peaked 5 days after stimulation
(Figure 1C). The level of PTPN22.1 transcript was approximately
100 times more than that of PTPN22.6, which was only modestly
induced anti-CD3 stimulation. Both PTPN22 transcript was
present at a very low (10
29 to 10
210 relevant to b-actin) or
undetectable level in a human colonic adenocarcinoma cell line,
HT-29, which does not express PTPN22 (data not shown and
Figure 2A). Although the level of PTPN22.1 or ‘‘total’’ transcript
was very comparable among the three donors, the level of
PTPN22.6 of donor #3 was approximately 60 times and 20 times
of that of donor #1 and donor #2, respectively, at almost all time
pointes. The efficiency of the primer pairs used in Figure 1C is
very comparable (see Methods). Therefore, the influence of primer
efficiency on the transcript level shown in Figure 1C is negligible.
Detection of the protein product of PTPN22.6 in human T
cells
We found that a commercially available antibody, anti-Lyp,
that is specific to human PTPN22 recognized several protein
species in human Jurkat T cells but not in HT-29 cells (Figure 2A).
The level of at least three (and possibly four) of the protein species,
including a dominant band corresponding to PTPN22.1, was
reduced in extract prepared from Jurkat cells transfected with
PTPN22 siRNA but not scrambled siRNA (Figure 2A), suggesting
that these three or four protein species are either alternatively
spliced products of PTPN22 or degradation products of
PTPN22.1. The PTPN22 siRNA contains four sequences. Three
of the four sequences are shared by both PTPN22.1 and
PTPN22.6. To confirm the presence of endogenous PTPN22.6
protein, we raised a rabbit antiserum specific to PTPN22.6. The
PTPN22.6 antibody thus generated was able to recognize
exogenous PTPN22.6 but not PTPN22.1 (Figure 2B). However,
it failed to detect endogenous PTPN22.6 (data not shown)
probably because of low protein level of endogenous PTPN22.6
and/or poor avidity of the antibody. We then subjected Jurkat cell
extract to immunoprecipitation with anti-Lyp antibody. The
immunoprecipitate was then probed with anti-PTPN22.6. Immu-
noprecipitation with anti-Lyp antibody yielded a dominant protein
band of expected molecular weight of PTPN22.6 (approximately
76 kd), which migrated slightly faster than FLAG-PTPN22.6 and
was recognized by anti-PTPN22.6 (Figure 2C). The level of this
protein band was markedly reduced in Jurkat cells transfected with
PTPN22 siRNA but not scrambled siRNA. No protein band with
a molecular weight equivalent to that of PTPN22.1 (approximately
92 kd) was detected. Thus, this 76 kd protein is not a degradation
product of PTPN22.1. Similar results were obtained when Jurkat
cell extract was first immunoprecipitated with anti-PTPN22.6 and
then probed with anti-Lyp antibody (data not shown).
To further confirm that the protein product of PTPN22.6 is
present in primary human Th cells, we harvested Th cells from
peripheral blood of healthy donors and transfected the Th cells
with PTPN22 siRNA, scrambled siRNA, or no siRNA. Cell
extract of the transfected cells was then subjected to immunopre-
cipitation with anti-Lyp antibody. Again, we were able to
precipitate a dominant protein band that was recognized by
PTPN22.6 antibody (Figure 2D). The level of this protein band
was reduced by PTPN22 siRNA but not scrambled siRNA. These
data collectively confirm the presence of protein product of
PTPN22.6 in human T cells.
PTPN22.6 can function as a dominant negative variant of
PTPN22.1
PTPN22.6 does not contain the entire PTP domain and has the
potential of acting as a dominant negative variant of PTPN22.1.
PTPN22.1 is known to attenuate NFAT activity [2]. Overexpres-
sion of PTPN22.1 in Jurkat cells expectedly suppressed NFAT-
dependent luciferase activity by approximately 50%. In contrast,
PTPN22.6 modestly increased NFAT activity in a dose dependent
manner (Figure 3A and 3C). To examine whether PTPN22.6 can
Figure 1. Alternatively spliced forms of human PTPN22. A.
Schematic diagrams of the human ptptn22 gene and putative protein
products of each isoform. Exons are numbered and white boxes
represent un-translated exons. The yellow box represents protein
tyrosine phosphatase (PTP) domain. The key catalytic region (HCSAGC)
and R620 are marked. The silver box after the PTP domain is the
inhibitory domain. The red boxes represent proline rich regions. The
brown two-headed arrows indicate the amplification products of real-
time PCR for each isoform. The exons constituting each isoform are
indicated. B. 293T cells were transfected with an expression vector
expressing indicated FLAG-PTPN22 isoforms. The protein levels of
FLAG-PTPN22 isoforms and Hsp90 in the transfected cells were
determined with Western blotting. The data shown is representative
of three independent experiments. C. cDNA was prepared from human
CD4+ T cells, which were stimulated in vitro with anti-CD3/anti-CD28 for
indicated periods of time, and subjected to real-time PCR analysis with
isoform-specific primers. The transcript levels thus obtained were
normalized against those of b-actin from the same samples. The data
shown are the results from three healthy donors.
doi:10.1371/journal.pone.0033067.g001
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PTPN22.1 and PTPN22.6 at various ratios. We found that
PTPN22.6, at a protein level less than a half of that of PTPN22.1,
completely nullified the effect of PTPN22.1 (Figure 3B), confirm-
ing the dominant negative nature of PTPN22.6.
The functional impact of the C1858T SNP is isoform-
dependent
It has been shown that W620PTPN22.1 was more potent than
R620PTPN22.1 in suppressing NFAT activity. But this gain-of-
function effect disappeared when both proteins were expressed at a
high level [2]. We independently confirmed this observation
(Figure 3C). Forced expression of R620PTPN22.1 attenuated
NFAT-driven luciferase activity in a dose-dependent manner.
W620PTPN22.1 was more efficient than R620PTPN22.1 in this
assay at 10 mg of plasmid DNA but not at 15 mg dose. We then
examined the impact of the C1858T SNP on NFAT activity in the
context of PTPN22.6. R620PTPN22.6 enhanced NFAT activity
in a dose-dependent manner but its effect peaked at 10 mgo f
plasmid DNA. W620PTPN22.6 comparably enhanced NFAT
activity up to 10 mg of plasmid DNA but its effect continued to
increase even at 15 mg of plasmid DNA. At this dose,
W620PTPN22.6 was more effective than R620PTPN22.6 in
enhancing NFAT activity.
We then expressed each of the four variants of PTPN22 in
primary human CD4+ T cells via amaxa nucleofection. Expres-
sion of both variants of PTPN22.1 resulted in a dose-dependent
reduction in IL-2 production. There was a trend of less IL-2
production with W620PTPN22.1 compared to R620PTPN22.1.
However, the difference was subtle and did not reach statistical
significance (Figure 3D). While R620PTPN22.6 had a negligible
effect, W620PTPN22.6 enhanced the production of IL-2 in a dose
dependent manner. It increased the level of IL-2 by 20–30% at a
protein level similar to that of R620PTPN22.6. As approximately
only a half of the cells were transfected, we estimated that
expression of W620PTPN22.6 would lead to a 40–60% increase in
cytokine production if we were able to achieve 100% transfection
efficiency. These results indicate that the impact of the C1858T
SNP on NFAT activity and T cell activation is isoform-dependent.
The level of PTPN22.6 positively correlates with disease
activity of RA
Our data suggest that the overall PTPN22 activity is dependent
on a functional balance between PTPN22.1 and PTPN22.6. An
increase in the level of PTPN22.6 can potentially disrupt this
functional balance and lead to hyperactivation of T cells, thereby
contributing to the pathogenesis of RA. To test this hypothesis, we
opted to examine the transcript level of PTPN22 isoforms in whole
peripheral blood of patients from the Brigham and Women’s
Hospital Rheumatoid Arthritis Sequential Study (BRASS) cohort.
We found that the transcript level determined with the PTPN22
primers was very comparable between whole peripheral blood and
purified un-stimulated T cells (comparing time 0 of Figure 1C and
Figure 4). We then quantified the transcript levels of PTPN22
isoforms in peripheral blood samples collected from randomly
selected 41 patients (one sample per patient). The average age was
54 (Table 1). All patients except two were female. Thirty-one out
of the forty-one patients (75.6%) were positive for rheumatoid
factor (RF) or anti-CCP. None of these patients were genotyped
for the C1858T SNP. The level of PTPN22.1 was 10 to 100 times
of that of PTPN22.6. There was no difference in the level of
PTPN22.1 or PTPN22.6 between sero-positive and sero-negative
populations. There was also no correlation between the level of
Figure 2. Detection of endogenous PTPN22.6 protein in human
T cells. A. Protein extract was prepared from HT-29 or Jurkat cells,
which were mock (M) transfected or transfected with PTPN22 specific
siRNA or scrambled (Sc) siRNA prior to harvest. The extract was analyzed
with Western blotting using Lyp antibody. The arrowheads indicate
protein species that are not present in HT-29 cells and are suppressed
by PTPN22 siRNA. B. 293T cells were transfected with the plasmid
vector expressing FLAG-PTPN22.1 or FLAG-PTPN22.6. The transfected
cells were then analyzed with Western blotting using PTPN22.6 and
Hsp90 antibody. C. Protein extract prepared from Jurkat cells described
in A was subjected to immunoprecipitation with anti-Lyp antibody or
control IgG. The immunoprecipitate along with protein extract
prepared from 293T cells expressing FLAG-PTPN22.6 were analyzed
with Western blotting using PTPN22.6 antibody. A fraction of Jurkat cell
extract was set aside prior to immunoprecipitation and was probed
with Hsp90 antibody to demonstrate equal input. IP and IB stand for
immunoprecipitation and immunoblot, respectively. D. Primary human
Th cells were harvested from healthy donors and expanded in vitro with
anti-CD3/atni-CD28 for 5 days. The cells were then transfected with
siRNA and subjected to immunoprecipitation as Jurkat cells described
in A and C. The data shown in A, B, and C are representative of at least
two independent experiments.
doi:10.1371/journal.pone.0033067.g002
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with DAS28-CRP3 (Disease Activity Score based on 28 joint
counts with 3 variables including C-reactive protein). However, we
found a linear and positive correlation (p=0.0084) between
PTPN22.6 and DAS-CRP3 even after adjusting for the potential
confounding factors, such as age and status of RF and anti-CCP.
Figure 3. PTPN22.6 is a dominant negative variant of PTPN22.1. A. Jurkat cells were transfected with a NFAT-luc reporter, 10 mg of pCMV2B
expressing indicated FLAG-PTPN22 isoforms, and a TK-Renilla reporter. The transfected cells were then stimulated with anti-CD3 overnight and the
luciferase activity was analyzed. Normalized firefly lucifease activity was calculated as described in Methods and was shown. The data shown are
cumulative results of at least three independent experiments. B. Jurkat cells were transfected with the NFAT-luc, TK-Renilla, 10 mg of pCMV2B-FLAG-
PTPN22.1, and increasing amount of pCMV2B-FLAG-PTPN22.6. Empty pCMV2B vector was added to equalize the total amount of expression vector in
each sample. Normalized luciferase activity was shown. The data shown in the top panel are cumulative results of at least three independent
experiments. The standard error bars are too narrow to see. pCMV2B-FLAG-PTPN22.1 and pCMV2B-FLAG-PTPN22.6 at the same ratio was used to
transfect 293T cells. The protein level of FLAG-PTPN22.1 and FLAG-PTPN22.6 in transfected 293T cells were quantified with Western blotting using
FLAG antibody. One representative Western blot is shown. C. Jurkat cells were transfected with NFAT-luc, TK-Renilla, and increasing amount of the
pCMV2B vector expressing indicated FLAG-PTPN22 protein. Transfected cells were stimulated and normalized luciferase activity was shown. The data
shown are cumulative results of at least three independent experiments. *p,0.05. In all luciferase experiments shown in A, B, and C, the normalized
luciferase activity obtained from cells transfected with empty pCMV2B and stimulated with anti-CD3 was arbitrarily set as 100. D. Primary human
CD4+ T cells were transfected with indicated amount (in mg) of pCMV2B vector expressing indicated FLAG-PTPN22 variants. In some transfections,
empty pCMV2B vector was added to bring up the total amount of expression vector to 5 mg. The transfected cells were stimulated with anit-CD3
(1 mg/ml) for 72 hours. The concentration of IL-2 in supernatant was measured with ELISA. The IL-2 level measured from cells transfected with empty
pCMV2B vector (300–700 pg/ml) was arbitrarily set as 100%. Cell extract of the transfected cells was also probed with anti-FLAG and anti-Hsp90
antibodies in a Western blot to show the level of various FLAG-PTPN22 proteins. The data shown are cumulative results of at least three independent
experiments. *p,0.05; **p,0.005. A representative Western blot is shown in the bottom panel.
doi:10.1371/journal.pone.0033067.g003
Figure 4. Expression of PTPN22 isoforms in RA patients. cDNA
was prepared from whole blood of 41 RA patients described in Table 1.
The cDNA was subjected to real-time PCR using PTPN22 isoform-
specific primers. The transcript level thus obtained was normalized
against that of b-actin obtained from the same sample and plotted
against DAS28-CRP3. Linear regression model was used to evaluate the
relationship between the transcript level and DAS28-CRP3. The p value
for slope estimate and R
2 of each model were shown.
doi:10.1371/journal.pone.0033067.g004
Table 1. Characteristics of study subjects.
Total Age Gender
aRF+ Anti-CCP+ RF+ or anti-CCP+
41 54613 39F, 2M 27 (65.9%) 27 (65.9%) 31 (75.6%)
RF: rheumatoid factor; CCP: citrullinated cyclic protein.
aThe status of RF in one patient is unknown.
doi:10.1371/journal.pone.0033067.t001
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Our data validate the existence of PTPN22.6 and demonstrate
that it is a dominant negative variant of PTPN22.1. The
expression of PTPN22.6 varies significantly among healthy
individuals. It will be of great interest to investigate in the future
whether T cells obtained from individuals expressing a high level
of PTPN22.6, such as donor#3, will be hyper-responsive to
stimulation. During the preparation of this manuscript, two
additional isoforms, NM012411 (isoform 2) and NM001193431
(isoform 3), were deposited in NCBI database. We have also found
in the NCBI database several cDNA sequences that may encode
additional PTPN22 isoforms. The function and expression of
isoform 2 (PTPN22.2) and 3 (PTPN22.3) and those potential
PTPN22 isoforms has yet to be examined.
Our data provide attractive explanations for two yet-to-be-
answered questions regarding the role of PTPN22 in RA. The first
question is whether and how the overall activity of PTPN22 is
altered in RA patients who do no carry the 1858T allele. One
reasonable answer is that the overall activity of PTPN22 is normal
in these patients. However, an alternative and intriguing scenario
is that the activity of PTPN22 is also perturbed in this group of RA
patients. A recent study indicates that the association between
PTPN22 and RA cannot be all accounted for by this SNP [22].
C1858 is not polymorphic in Asian and African populations but
several SNPs in the promoter region of PTPN22 are associated
with RA in Han Chinese [23]. These observations strongly
support the alternative explanation. Our data suggest that one
plausible way of perturbing the overall activity of PTPN22 is to
alter the level of PTPN22.6, and possibly other isoforms. This
scenario can be examined by comparing the expression of
PTPN22.6 in various subsets of immune cells between RA
patients and healthy individuals.
The second and more puzzling question is why there is
conflicting data regarding the effect of the 1858T allele on the
activation of lymphocytes. The R-to-W conversion resulted in a
gain in the phosphatase activity of PTPN22 and attenuated TCR-
induced NFAT activity [2,15]. However, co-expression of
W620PTPN22 and Csk unmasked the 1858T allele as a
hypomorph [16]. During the preparation of this manuscript,
Zhang et al reported that the R-to-W conversion led to a
hypomorphic PTPN22 due to enhanced degradation by calpain 1
[17]. We however found no appreciable effect of the C1858T SNP
on the level or stability of PTPN22 proteins. Zhang et al further
showed that human T cells that were homozygous for the 1858T
allele were hyper-responsive to stimulation. This latter finding
however contradicts a previous publication showing that the
1858T allele attenuated anti-CD3-induced calcium influx in
human T cells in a gene dose-dependent manner [18].
Our data show that the impact of the C1858T SNP on T cell
activation is actually isoform-dependent. Although the R-to-W
conversion enhances the phosphatase activity of PTPN22.1 and
attenuates NFAT activity in vitro, this conversion in the context of
PTPN22.6 reciprocally boosters the activation of Th cells. This
effect will be even more profound in T cells expressing a higher
level of PTPN22.6, such as those from donor#3. Thus one
plausible explanation for the aforementioned conflicting results is
that the effect of the 1858T allele on T cell activation is dependent
on the ratio between PTPN22.1 and PTPN22.6. It results in hypo-
responsiveness in T cells with a low PTPN22.6/PTPN22.1 ratio
but hyper-responsiveness in those with a high ratio.
Despite the positive correlation between the level of PTPN22.6
and RA activity, it needs to be mentioned that we measured the
level of PTPN22 isoforms in peripheral blood instead of purified
cell populations. Our real-time PCR assay did not allow us to
determine the contribution of each subset of blood cells, many of
which express PTPN22. It is likely that the elevated level of
PTPN22.6 seen in our RA patients with higher disease activity is
contributed by one single or a few subsets of blood cells. In this
scenario, the level of PTPN22.6 in those subsets of blood cells will
be a more sensitive indicator of disease activity than that in
peripheral blood. It is also unclear whether the elevated level of
PTPN22.6 is a cause or an epiphenomenon of higher RA activity.
Prospective studies longitudinally monitoring the level of
PTPN22.6 in RA patients will be needed to address this important
question.
Supporting Information
Figure S1 Comparison of the peptide sequence between
PTPN22.1 and PTPN22.6 (AK310570).
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